Search

Lemuteporfin

Lemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer. It is intended for the treatment of beign prostatic hyperplasia.

Amrubicin

Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer … Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC.

Hydrocortisone phosphate

Serotonin

Not evaluated by the FDA, homeopathic product.

CGC-11047

CGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis.

Alfimeprase

Alfimeprase is being developed by Nuvelo.

Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen

Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen is a vaccine for intramuscular injection used in the prevention of invasive disease caused by *Haemophilus … b capsular polysaccharide (polyribosyl-ribitol-phosphate, PRP), a high-molecular-weight polymer prepared from the *H. influenzae* type b strain 1482 grown in a semi-synthetic medium, covalently bound to

RPI-78M

Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).

BTA9881

BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.

Dexrazoxane

It appears to inhibit formation of a toxic iron-anthracycline complex.